TRAIL受体DR5、DcR1在子宫内膜癌中的表达及临床意义  

Expression and clinical significance of DR5 and DcR1 for TNF-related apoptosis-inducing ligand (TRAIL) in endometrial carcinoma

作　　者：高庆[1] 曲群[1] 陈青娟[1] 赵玲[1] 王桂贤[1] 马玉琴[1] 杜稳侠[1] 

机构地区：[1]西安交通大学第二附属医院妇产科,陕西西安710004

出　　处：《现代肿瘤医学》2009年第9期1746-1749,共4页Journal of Modern Oncology

基　　金：陕西省科学技术攻关项目[2004K18-G9(a)];西安交通大学医学院第二医院课题(2003-YL-34)

摘　　要：目的:探讨肿瘤坏死因子相关凋亡诱导配体(TRAIL)受体DR5、DcR1在子宫内膜癌中的表达及临床意义。方法:采用免疫组化ElivisionTMplus法检测DR5、DcR1在10例正常子宫内膜、12例增生性子宫内膜及42例子宫内膜癌中的表达。结果:子宫内膜癌中DR5的阳性表达率为36/42(85.71%),明显高于正常子宫内膜3/10(30.00%),(P<0.01)。正常子宫内膜中DcR1的阳性表达率为100.00%,明显高于子宫内膜癌19/42(45.24%),(P<0.01)。在子宫内膜癌中,DR5的阳性表达与病理分级及肌层浸润呈反比。结论:子宫内膜癌中DR5的高表达使TRAIL用于子宫内膜癌的治疗在理论上具有可行性;子宫内膜癌中DcR1的表达可能导致TRAIL诱导的凋亡耐受。Objective：Tumor necrosis factor- related apoptosis -inducing ligand （TRAIL） selectively kill tumor cells, but spare normal cells through engagement of its receptors. This study aims to investigate the differential expression and clinic significance of DR5 and DcR1 for TRAIL receptors in endometrial carcinoma. Methods： Adopting immunohistochemistry ElivisionTM plus method to detect the expression of DR5 and DcR1 for TRAIL receptors in human normal endometrium, endometrial hyperplasia and endometrial carcinoma. Results： Positive expression of DR5 in endometrial carcinoma was 85.71% , which was much higher than that in normal endometrium 30. 00% （ P 〈 0.01 ）. The positive rate of DcR1 （ 100.00% ） in normal endometrium was significantly higher than the rate（45.24% ） in endometrial carcinoma（ P 〈 0.01 ）. In endometrial carcinoma, the expression of DR5 had negative correlation with the cancer tissue differentiation grade and the myometrium invasion. Conclusion： The high expression of DR5 in en- dometrial carcinoma cells had made TRAIL applying in treating endometrial carcinom possible in theory; The high expression of DcR1 in endometrial carcinoma cells might cause carcinoma cells to produce tolerance of apoptosis induced by TRAIL.

关 键 词：子宫内膜癌 DR5 DCR1 免疫组织化学法 凋亡 

分 类 号：R737.33[医药卫生—肿瘤]